Navigation Links
The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
Date:2/22/2011

licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged,
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
6. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
7. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2
... Technology is revolutionizing healthcare — making it more ... cost of care. AT&T ,s* new set of ... designed to do just that. The 2011 Frost & ... AT&T for its approach to mHealth, recognizing the company,s ...
... -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare ... recently listed as one of the Deloitte & Touche,s ... growth over the past three years. Beijing-headquartered ... its operating revenues rising more than 270% on average ...
Cached Medicine Technology:Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 3Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 4Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
(Date:3/2/2015)... 02, 2015 Secura Consultants announced ... with First Protective Insurance Group of Birmingham, AL ... First Protective affiliated advisors to access the enhanced ... Secura Consultants delivers. , Secura Consultants, ... in the design and implementation of insured income ...
(Date:3/1/2015)... 2015 As residents and business ... Michael Burns and Carita Weaver, believe in supporting ... with the Southlake Chamber of Commerce, Carroll Independent ... recently launched a website for Southlake mayoral candidate ... communications tool for Hill’s campaign, the website combines ...
(Date:3/1/2015)... 01, 2015 Comparing a new source ... using the Quotes Pros portal this year. A broad ... insurance rates that are being supplied through the finder ... agencies and prices available for each policy is now ... Every system user will first be asked to present ...
Breaking Medicine News(10 mins):Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2
... families are involved, study finds , FRIDAY, June 12 ... of an incurable genetic disease isn,t worry enough, people ... discriminated against by insurance companies, relatives and in social ... and colleagues at the University of British Columbia surveyed ...
... , ATLANTA, June 12 Salient Mobility LLC, ... of the 2009 " Text For a Cause(TM) " campaign, ... from organizations such as the Georgia Cancer Foundation . ... campaign begins August 24th, and culminates with the issuance of ...
... 12 June 2009: Three new studies have individually shown ... effective, with a good safety profile, in children under ... and associated with improved Health-Related Quality of Life (HRQoL) ... data are being presented at the Paediatric Rheumatology European ...
... five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% ... benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ... AS patients had no arthritis and 84.9% had no ... Over this period, patients continued to show a sustained ...
... National Quality Forum (NQF) has tapped Thomas B. Valuck, ... Strategic Partnerships. Dr. Valuck comes to NQF from the ... was both Medical Officer and Senior Adviser in the ... a unique, multi-stakeholder, nonprofit organization dedicated to improving the ...
... Medifast, Inc. (NYSE: MED ) today announced ... corporate-owned Medifast Weight Control Centers. Earlier in the year, the ... out, and analyze the success of the model throughout the ... be expanding its investment in this area. , , ...
Cached Medicine News:Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Salient Mobility Launches the 'Text For a Cause(TM)' Campaign in Raising Awareness Through Wireless Health Tips 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 2Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 3Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3
... Bausch & Lomb PreserVision® AREDS formula ... and mineral supplement clinically proven effective in ... Age Related Eye Disease Study (AREDS). , ... and mineral supplement with the antioxidant vitamins ...
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Easy-to-use desktop QC data management solution...
Medicine Products: